Two-drug regimens might be as effective as three-drug regimens for HIV-1 infections
KEY POINT
The fixed-dose combination regimen of dolutegravir/rilpivirine (Juluca—ViiV Healthcare) administered as one tablet daily was found to be noninferior to traditional three-drug antiviral regimens for management of HIV-1 infections, according to pooled results from the SWORD-1 and -2 trials published in Lancet.
SOURCES
Llibre JM, et al. Efficacy, safety, and tolerability of dolutegravir–rilpivirine for the maintenance of virological suppression in adults with HIV-1: Phase 3, randomized, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018;391(10123):839–49.
Boyd MA, et al. Combination ART: Are two drugs as good as three? Lancet. 2018;391(10123):817–9.
